Merck(US:MRK) Prnewswireยท2025-02-20 15:51Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Merck & Co., Inc. related to misleading statements about Gardasil's expected revenue and demand in China, with a deadline for investors to seek lead plaintiff status in a federal securities class action by April 14, 2025 [2][4]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses exceeding $100,000 in Merck between February 3, 2022, and February 3, 2025, to discuss their legal rights [1]. - The complaint alleges that Merck and its executives violated federal securities laws by making false statements regarding Gardasil's revenue expectations and demand in China [4]. - The firm has recovered hundreds of millions of dollars for investors since its founding in 1995, indicating a strong track record in securities litigation [3]. Group 2: Financial Performance and Market Reaction - On February 4, 2025, Merck reported a 3% decline in GARDASIL/GARDASIL 9 sales to $8.6 billion and announced a temporary pause in shipments to China [5]. - Following the announcement, Merck's stock price fell by $9.05 per share, or 9.1%, closing at $90.74 per share [5]. Group 3: Class Action Details - The lead plaintiff in a class action is the investor with the largest financial interest who directs the litigation on behalf of the class [6]. - Any member of the putative class can move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [6].